FDA

The FDA expanded the approval for teplizumab (Tzield), a biologic that delays the progression of preclinical type 1 diabetes to the symptomatic form, to include treatment in kids as young …

Breakthrough T1DTzield approved for children ages one and older in stage 2 T1DThe U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type …

The U.S. Food & Drug Administration announced that a glucose meter (a.k.a. a blood sugar meter) company is issuing an important correction for its blood glucose monitoring system.True Metrix is …

There’s good news on the horizon for people at risk for a type 1 diabetes (T1D) diagnosis, especially parents of young children. Sanofi recently announced that its drug to delay …

A person wears the MiniMed 780G pump on the hip with the Instinct sensor on the arm. [Image courtesy of Medtronic] Medtronic (NYSE:MDT) today announced three U.S. milestones expanding access …

GALWAY, Ireland, Feb. 22026 /PRNewswire/ — Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice, and flexibility for people living …

The US Food and Drug Administration (FDA) has approved an updated label for insulin human (Afrezza) inhalation powder, which provides guidance for starting dosages when switching from multiple daily injections …

MiniMed Go™ is the first and only smart MDI system that automatically integrates insulin dosing and glucose data in a single app to provide empowering insights for individuals on multiple …

The US Food and Drug Administration has accepted for Priority Review a supplemental biologic license application for Tzield (teplizumab-mzwv) to expand its age indication to include children as young as …

The FDA has accepted for priority review a supplemental biologics license application (sBLA) for teplizumab-mzwv (Tzield; Sanofi) that seeks to expand the current age indication from 8 years and older …